anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A water-in-oil emulsion comprises 1 to 85 wt. per cent of water dispersed in a siloxane copolymer comprising 60 to 95 wt. per cent of <FORM:1021044/C3/1> units, where each R is a monovalent hydrocarbon group at least 60% thereof being C1- 4 alkyl and each a is 0, 1, 2 or 3 and the average a is between 1.9 and 2.5, and 40 to 5 wt. per cent of polyoxyethylene and/or propylene units having at least three oxy atoms and linked to silicon by Si-O-C- linkages with the remaining valencies satisfied by H atoms.  Such copolymers may be obtained by reacting a siloxane of the unit formula <FORM:1021044/C3/2> , where A is a hydrolysable atom or group and y the number of polyoxyalkylene groups to be introduced-with a polyoxyalkylene diol HO(CnH2nO)xH in the presence of a condensation or esterification catalyst.  The emulsions may be used as cosmetic and protective ointments for the skin and may incorporate the additives commonly used in cosmetic and pharmaceutical preparations such as perfumes; pigments; fillers, e.g. zinc or titanium oxide or silicas; sunscreen agents and medicaments.ALSO:A water-in-oil emulsion comprises 1 to 85 wt. % of water dispersed in a siloxane copolymer comprising 60 to 95 wt. % of <FORM:1021044/A5-A6/1> units, where each R is a monovalent hydrocarbon group at least 60% thereof being C1-4 alkyl and each a is 0, 1, 2 or 3 and the average a is between 1.9 and 2.5, and 40 to 5 wt. % of polyoxyethylene and/or propylene units having at least three oxy atoms and linked to silicon by Si-O-C-linkages with the remaining valencies satisfied by H atoms.  Such copolymers may be obtained by reacting a siloxane of the unit formula <FORM:1021044/A5-A6/2> where A is a hydrolysable atom or group and y the number of polyoxyalkylene groups to be introduced-wwith a polyoxyalkylene diol HO(CnH2nO)xH in the pressence of a condensation or esterification catalyst.  The emulsions may be used as cosmetic and protective ointments for the skin and may incorporate the additive commonly used in cosmetic and pharmaceutical preparations such as perfumes; pigments; fillers e.g. zinc or titanium oxide or silicas; sunscreen agents and medicaments.
Patients with radiorecurrent prostate cancer have few viable treatment options, both in terms of efficacy and morbidity. Local therapies fail even in highly selected patients due to locally advanced disease, microscopic metastases, and a worsening of the biology of cancer cells. Furthermore, attempts at salvage local treatments have the complications of incontinence, impotence and in some cases unremitting penile pain. Pre-clinical studies in a mouse model of prostate cancer have noted the potential benefit of adenovirus-mediated gene therapy to deliver IL-12 in this clinical scenario. This treatment was able to significantly growth suppress the injected tumor to prolong survival and reduce the number of pre-established metastases. The mechanisms underlying this activity involved both innate immunity (neutrophils and natural killer \[NK\] cells) and acquired immunity ( T cells) and enhanced expression of Fas to further sensitize Fas/Fas ligand (FasL) killing.

This is a Phase I study. Therefore, the primary objective is finding the Maximum Tolerated Dose. Within this realm will be monitoring of pro-inflammatory cytokines. Secondary aspects will involve correlating important mechanisms identified in the pre-clinical model: induction of T cells.
PROBLEM TO BE SOLVED: To obtain the subject therapeutic agent/prophylactic developing a strongly bactericidal effect on a specific bacterium, safer and more effective than a conventional therapy of concomitant use of medicines by making the therapeutic agent/prophylactic include an agglutination active factor to the bacterium and an acid secretion, inhibitor. SOLUTION: The therapeutic agent/prophylactic comprises (A) an agglutination active factor to a bacterium of the genus Helicobacter and (B) an acid secretion inhibitor. The component A is preferably a polyclonal body derived from an egg of fowl. The component B is preferably a histamine H2 receptor blocking agent and/or a proton pump inhibitor. The bacterium is preferably at least one kind selected from the group consisting of Helicobacter pylori, Helicobacter cinaedi, Helicobacter fennelliae, Helicobacter heilmannii, Helicobacter rappini, etc. In the component A, in the case of a polyclonal antibody having >=256 agglutination antibody titer, preferably 10 mg to 10 g/50 kg B.W. per time of the polyclonal antibody is orally administered.
The proposed study aims to test the efficacy of the Latina Friends Motivating the Soul (ALMA) intervention in a delayed intervention control trial. ALMA is an 8-week program offered in a group format to teach women new coping strategies and enhance their social ties and social support to prevent and reduce their depression and anxiety. Aim 2 is to determine the efficacy of the ALMA intervention to reduce depressive and anxiety symptoms using a delayed intervention control study design. The investigators will recruit women from community-based organizations serving Latino immigrants to participate in the program, which will be offered in community settings. The investigators will assess process outcomes of recruitment, retention, fidelity, and participant satisfaction through observations and in-depth interviews with participants. The investigators will assess the efficacy of the intervention by comparing changes in women's depressive and anxiety symptoms in the intervention and attention control groups at four time points (baseline, 3-month follow-up, 6-month follow-up, and 9-month follow-up). Aim 3 is to assess the potential impact of the intervention on both individual (stigma, stress, coping strategies) and interpersonal (social support, social ties) factors, and whether the impact of the intervention is mediated by these factors. The research team includes investigators in psychology, medicine, social work and public health, as well as community-based organizations serving Latina immigrants. The study uses rigorous methods to test an innovative program that integrates both culturally relevant and evidenced-based strategies to address significant mental health disparities in a high-risk and underserved population. Findings will help inform future research and practice. Given the growth of the Latino population, identifying interventions that reduce mental health disparities among Mexican immigrant women can have a significant public health impact.
PURPOSE: A composition containing L-threlonate for preventing or treating hair loss is provided to suppress DKK-1 expression and keratinocyte proliferation. CONSTITUTION: A composition for preventing or treating hair loss contains threonate as an active ingredient. Threonate is calcium L-threonate, sodium L-threonate, chrome L-threonate, or iron L-threonate. Hair loss is caused by androgen. Threonate is contained in 0.1-20 weight% based on total weight. The composition is used in the form of liquid, cream, suspension, gel, solution, lotion or oil.
Objective: While nonnorepinephrine vasopressors are increasingly used as a rescue therapy in cases of norepinephrine-refractory shock, data on their efficacy are limited. This systematic review and meta-analysis aims to synthesize existing literature on the efficacy of angiotensin II (ATII) in distributive shock. Methods: We preregistered our meta-analysis with PROSPERO (CRD42023456136). We searched PubMed, Scopus, and gray literature for studies presenting outcomes on ATII use in distributive shock. The primary outcome of the meta-analysis was all-cause mortality. We used a random effects model to calculate pooled risk ratio (RR) and 95% confidence intervals (CIs). Results: By incorporating data from 1,555 patients included in 10 studies, we found that however, all-cause mortality was similar among patients receiving ATII and controls (RR = 1.02; 95% CI: 0.89 to 1.16, P = 0.81), the reduction in norepinephrine or norepinephrine-equivalent dose at 3 h after treatment initiation was greater among patients receiving ATII (MD = -0.06; 95% CI: -0.11 to -0.02, P = 0.008), while there were no higher rates of adverse events reported among ATII patients. Conclusions: While ATII did not reduce mortality among distributive shock patients, it allowed for significant adjunctive vasopressor reduction at 3 h without an increase in reported adverse events, deeming it a viable alternative for the increasingly adopted multimodal vasopressor for minimizing catecholamine exposure and its adverse events.
Single Nucleotide Variant (SNVs) affect gene expression as well as protein structure and activity, leading to reduced signaling capabilities and ultimately, increasing cancer risk. SOCS3 (suppressor of cytokine signaling 3), a critical tumor suppressor providing a substantial part in the feedback loop of the JAK/STAT pathway, is abnormally suppressed in various cancer. This study aims to screen non-coding and potentially deleterious coding SNVs in the SOCS3 gene. We performed six programs: PredictSNP1.0 (predicting Deleterious nsSNVs), ConSurf (analyzing sequence conservation), ModPred (analyzing SNVS in PTMs sites), I-Mutant and MUpro (to analyze SNVs effecting protein stability), and molecular docking and molecular dynamics (MD) (to assess the consequences of SOCS3 genetic variations on JAK interactions) for coding regions and three programs (UTRSite, SNP2TFBS, miRNA SNP) (to analyze SNVs effecting the gene expression) in non-coding regions, respectively. After screening 2786 SOCS3 SNVs, we found 10 SNVs, as well as 49 SNPs that change the function of non-coding areas. Out of 10 selected nsSNVs, 3 SNVs (W48R, R71C, N198S) predicted to be the most damaging by all the software programs, as well as one nsSNV (R194W) could be highly deleterious from Molecular Docking analysis combined with MD Simulations. Our findings propose a procedure for studying the structure-related consequences of SNVs on protein function in the future.Communicated by Ramaswamy H. Sarma.
The invention relates to a composite Chinese herbal medicine pig feed additive containing eucommia ulmoides powder. The feed additive employs Chinese herbal medicines, a microecological preparation and other nutrients for organic combination and scientific compatibility, and the compositions complement each other, draw the strong points of others to offset own weakness, cooperate with each other and act together after mutual compatibility. Gypsum rubrum has the efficacy of clearing heat and purging fire, and has the efficacy of detoxifying and dispersing abscesses, clearing deficiency-type heat, tonifying the middle and tonifying qi by being cooperatively used with herba abri, herba eupatorii and eucommia ulmoides leaf dry powder. Herba sedi and herba moslae have the efficacy of draining dampness and removing icterus, clearing heat and detoxifying, and resolving dampness and harmonizing the middle. After being added into common pig feed, the feed additive is capable of accelerating growth speed of health pigs, improving immunity, preventing pig influenza and reducing morbidity rate. Also only after an influenza-attacked pig eats feed added with the feed additive, the recovery speed is fast, feed intake is increased, spirit state recovery is good, and growth behavior is excellent.
DOSAGE MUST BE INDIVIDUALIZED. The recommended starting dose of Carvedilol Phosphate extended-release capsules is 20 mg once daily. If this dose is tolerated, using standing systolic pressure measured about 1 hour after dosing as a guide, the dose should be maintained for 7 to 14 days, and then increased to 40 mg once daily if needed, based on trough blood pressure, again using standing systolic pressure 1 hour after dosing as a guide for tolerance. This dose should also be maintained for 7 to 14 days and can then be adjusted upward to 80 mg once daily if tolerated and needed. Although not specifically studied, it is anticipated the full antihypertensive effect of Carvedilol Phosphate extended-release capsules would be seen within 7 to 14 days as had been demonstrated with immediate-release carvedilol. Total daily dose should not exceed 80 mg.

Concomitant administration with a diuretic can be expected to produce additive effects and exaggerate the orthostatic component of carvedilol action.
Vascular calcification (VC) has emerged as a key predictor of cardiovascular events in patients with chronic kidney disease (CKD). In recent years, an expanding body of research has put forth the concept of accelerated vascular aging among CKD patients, highlighting the significance of vascular cells senescence in the process of VC. Within the milieu of uremia, senescent vascular endothelial cells (VECs) release extracellular microvesicles (MV) that promote vascular smooth muscle cells (VSMCs) senescence, thereby triggering the subsequent osteogenic phenotypic switch and ultimately contributing to the VC process. In addition, senescent vascular progenitor or stem cells with diminished ability to differentiate into VECs and VSMCS, compromise the repair of vascular integrity, on the other hand, release a cascade of molecules associated with senescence, collectively known as the senescence-associated secretory phenotype (SASP), perpetuating the senescence phenomenon. Furthermore, SASP triggers the recruitment of monocytes and macrophages, as well as adjacent VECs and VSMCs into a pro-adhesive and pro-inflammatory senescent state. This pro-inflammatory microenvironment niche not only impacts the functionality of immune cells but also influences the differentiation of myeloid immune cells, thereby amplifying the reduced ability to effectively clear senescent cells of senescent macrophages, promoted calcification of VSMCs. The objective of this paper is to provide a comprehensive review of the contribution of vascular cell senescence to the emergence and advancement of VC. Gaining a comprehensive understanding of the involvement of cellular senescence within the vessel wall is pivotal, especially when it comes to its intersection with VC. This knowledge is essential for advancing groundbreaking anti-aging therapies, aiming to effectively mitigate cardiovascular diseases.
Compositions for treating viral and bacterial diseases are described. The compositions contain a synthetic soil phenolic polymeric material which contains sulfur, boron, alkaline earth, or transition metals but does not contain nitrogen. The synthetic materials may be synthetic humic acids or fulvic acids. The polymeric materials in the compositions are prepared by oxidizing one or more organic phenols in the presence of inorganic salts. Polymeric materials prepared from organic phenols having at least one carboxylic acid group are especially effective. The compositions can be injected, applied topically, ingested, inhaled, or applied as a suppository.
Disclosed is a composition that is suitable for self-tanning, said composition comprising 5 to 30% w/w of a skin tanning agent; 3 to 20% w/w of one or more surfactants; 1 to 20% w/w of one or more delivery agents; 0.1 to 4% w/w of one or more film forming agents; 0.1 to 1% w/w of one or more skin conditioning or soothing agents; 0.1 to 3% w/w of one or more thickeners, preservatives, stabilising agents or combinations thereof; and water. Preferably, the skin tanning agent is dihydroxyacetone (DHA). Most preferably, the surfactant comprises sodium laureth sulphate and cocamidopropyl betaine. Most preferably, the delivery agent comprises both propylene glycol and glycerine. Preferably, the skin conditioning agent is betaine. Preferably, the thickener is sodium chloride, hydroxyethylcellulose or a combination of the two. Also provided is a sunless or self-tanning product comprising the composition and a method of delivering the tanning agent to the skin of a user.
Pleural space infections portend considerable morbidity and require procedural and sometimes surgical intervention in the context of prolonged hospital stays (median length of stay has been reported as 14-19 days) for definitive management. Key aspects of management include pleural space evacuation and appropriate antimicrobial therapy. The antimicrobial regimen is initiated intravenously and is often transitioned to an oral regimen as guided by clinical improvement, radiographic improvement, and microbiologic studies though conventional bacterial cultures remain negative in as many as 40% of cases of pleural space infection. There is variability in antimicrobial duration though this is typically continued for at least 3 weeks. The MIST 2 trial investigated the role of intrapleural tissue plasminogen activator (t-PA) and dornase (DNase) in the management of pleural space infections, noting that disrupting septations and reducing pleural fluid viscosity were necessary steps to achieve successful drainage in in-vitro studies. MIST 2 demonstrated that a combination of intrapleural t-PA and DNase improved pleural space evacuation on serial chest x-ray and reduced the frequency of surgical referral and hospital length of stay.

Saline irrigation of the pleural space has been proposed to reduce stasis and dilute bacteria, cytokines, and coagulation factors, which induce pleural space organization. The Pleural Irrigation Trial was a pilot study evaluating the role of 250 cc 0.9% sodium chloride irrigation three times daily for 3 days in comparison to standard care, which included maintaining thoracostomy tubes on suction and flushing with 30 cc three times daily. Saline irrigation led to a 32.3% reduction in pleural fluid volume as assessed by computed tomography in comparison to 15.3% in the standard care arm. Fewer patients in the irrigation group were referred for surgery (OR 7.1).

To our knowledge, the efficacy of intrapleural saline irrigation in addition to fibrinolytic therapy has not been studied in comparison to fibrinolytic therapy alone. The Mayo Clinic Interventional Pulmonary practice in Rochester, MN intends to study this in the context of the inpatient pleural service, the team that is routinely consulted for patients with proven or suspected pleural space infections. This team routinely places and manages ultrasound-guided locking-loop thoracostomy tubes and additionally manages patients with thoracostomy tubes placed by intensivists, surgeons, and interventional radiologists when consulted. Our team intends to recruit hospitalized patients that meet the inclusion/exclusion criteria of the study. Those that provide informed consent to participate in the study will be randomized to usual care versus intrapleural saline irrigation + usual care.
Participants with CLL, who are prior B-cell receptor (BCR) inhibitor naive, receive new formulation of entospletinib 100 mg (1 × 100 mg tablet) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
A composition containing a zeolite and an acid suitable for use in increasing bone strength in an animal having a bone strength less than desired and/or for use in treating, preventing or delaying the onset of a bone disorder such as osteoporosis, osteochondrosis, or dyschondroplasia. A preferred zeolite is zeolite A. Preferred acids are illustrated by citric, fumaric and aspartic acids. The presence of such acids in the composition enhances the breakdown (i.e. decomposition) of the zeolite thereby making it more efficacious for increasing bone strength or combating bone disease. Preferably, the compositions contain from about 35 to about 65 weight percent of the acid; the remainder being the zeolite. Such compositions can be admixed with other materials such as excipients used in the preparation of unit dosage forms.
YUFLYMA is intended for use under the guidance and supervision of a physician. A patient may self-inject YUFLYMA or a caregiver may inject YUFLYMA using either the YUFLYMA AI or YUFLYMA prefilled syringe if a physician determines that it is appropriate, and with medical follow-up, as necessary, after proper training in subcutaneous injection technique.

YUFLYMA can be taken out of the refrigerator for about 15 to 30 minutes before injecting to allow the liquid to come to room temperature. Do not remove the cap or cover while allowing it to reach room temperature. Do not shake. Carefully inspect the solution in the YUFLYMA AI or YUFLYMA prefilled syringe for particulate matter and discoloration prior to subcutaneous administration. If particulates and discolorations are noted, do not use the product. YUFLYMA does not contain preservatives; therefore, discard unused portions of drug remaining from the syringe.

Instruct patients using the YUFLYMA AI or YUFLYMA prefilled syringe to inject the full amount in the syringe, according to the directions provided in the Instructions for Use [see Instructions for Use].

Injections should occur at separate sites in the thigh or abdomen. Rotate injection sites and do not give injections into areas where the skin is tender, bruised, red or hard.

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.
Participants will receive methoxy polyethylene glycol-epoetin beta (MIRCERA) IV injection at a starting dose based on an intermediate conversion factor from their previous Erythropoiesis-stimulating Agent (ESA) dose (4 \* previous weekly epoetin dose \[international units {IU}\]/250 or 4 \* previous weekly darbepoetin alfa dose \[micrograms {mcg}\]/1.1) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with hemoglobin (Hb) level within ± 1 grams per deciliter (g/dL) of their baseline Hb level and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
Nerves are localized at an ultrasound-guided level and with respect to the vascular-nervous package two acupuncture needles are inserted, one for each nerve. The stimulation is the same as the TENS group: 10 stimulations x 10 times x 10 seconds, evoking the maximum contraction without pain.
PROBLEM TO BE SOLVED: To provide a health and beauty improving device capable of treating various diseases in a human body by synergy of light quantum energy and Chinese medicines, and further maintaining a good health and obtaining beautification effects.SOLUTION: The device includes a magnetic force generating section 2, an ore energy generating section 5, a first catalyst functioning section 6, a color energy generating section 7, a second catalyst functioning section 8, a Chinese medicine section 9 which are sequentially superposed and arranged. The magnetic force generating section 2 is formed by spirally winding and arranging a wire-like conductive material 4 on a base plate 3. The ore energy generating section 5 is formed by applying an ink containing a predetermined pulverized natural ore onto a composite resin sheet. The color energy generating section 7 is formed by laminating a red material layer, an orange material layer, a yellow material layer, a green material layer, a blue material layer, a dark blue material layer and a purple material layer sequentially from the ore energy generating section 5 side. The Chinese medicine section 9 contains given Chinese medicine. The catalyst functioning sections 6, 8 are each made of a sheet material containing gold and silver powder or a layered silicone resin or fabric.
The ESWT group will will meet the therapist twice in the first week, and once a week after it. ESWT will be applied to the iliotibial band and tensor fascia latae with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session.